Omentin: Linking Metabolic Syndrome and Cardiovascular Disease

Author(s): Ji-Yin Zhou, Lawrence Chan, Shi-Wen Zhou.

Journal Name: Current Vascular Pharmacology

Volume 12 , Issue 1 , 2014

Submit Manuscript
Submit Proposal

Abstract:

Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.

Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 1
Year: 2014
Page: [136 - 143]
Pages: 8
DOI: 10.2174/1570161112999140217095038

Article Metrics

PDF: 52